Biologics in gastroenterology

Speciality: Gastroenterology


Speaker:

Dr. R S Arun | Senior Consultant Gastroenterologist

Description:

A warm welcome to all the medical professionals in this interesting session on Biologics in gastroenterology.
Biologics have revolutionized the treatment of several gastrointestinal disorders, particularly inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. These advanced therapies target specific molecules in the immune system, such as TNF-alpha or interleukins, which play key roles in the inflammation that drives these conditions. By reducing inflammation at the molecular level, biologics help control symptoms, promote healing of the gut lining, and prevent flare-ups.
In clinical practice, biologics like infliximab, adalimumab, and ustekinumab are used when conventional treatments fail to provide adequate relief. They have significantly improved the quality of life for patients with moderate to severe IBD, offering long-term disease control and reducing the need for surgery. Although biologics are highly effective, they do come with risks, including an increased chance of infections, requiring careful monitoring. As research advances, biologics continue to expand treatment options in gastroenterology, offering hope for patients with difficult-to-manage conditions.
Therefore, get an overall knowledge of Biologics in gastroenterology. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer

4.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot